Applied Therapeutics Provides Regulatory Update on Govorestat for the Treatment of Classic Galactosemia

- Company completed Late-Cycle review meeting with FDA - FDA no longer intends to hold Advisory Committee meeting - FDA Review of NDA continues to proceed as planned with PDUFA target action date of November 28, 2024